Zandy Forbes’ biotech company MeiraGTx has developed targeted gene therapy methods to treat more than just genetic disorders. Now it’s on the cusp of its first regulatory approval. Each year ...
RBC Capital raised the firm’s price target on MeiraGTx (MGTX) to $13 from $11 and keeps an Outperform rating on the shares after its Q4 ...
BofA analyst Alec Stranahan raised the firm’s price target on MeiraGTx (MGTX) to $14 from $12 and keeps a Buy rating on the shares, citing a strengthened cash position after announcing a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback